IRA Drug Negotiation: First 10 Drugs and Price Reductions
| Drug | Use | List Price/Month (Approx.) | Negotiated Price | Discount |
|---|---|---|---|---|
| Eliquis | Blood thinner (afib, clots) | ~$550 | ~$197 | -64% |
| Jardiance | Diabetes / heart failure | ~$620 | ~$197 | -68% |
| Xarelto | Blood thinner | ~$520 | ~$197 | -62% |
| Stelara | Crohn's / psoriasis | ~$13,800/injection | ~$2,880 | -79% |
| Enbrel | Rheumatoid arthritis | ~$7,000/month | ~$2,355 | -67% |
| Imbruvica | Blood cancer (CLL/MCL) | ~$14,000/month | ~$9,319 | -38% |
| Entresto | Heart failure | ~$730 | ~$295 | -60% |
The Senior Voter Political Dynamic
Drug prices are the #2 issue for voters aged 65 and older, trailing only Social Security solvency and closely tracked alongside Medicare policy. This demographic votes at extraordinarily high rates — 71% turnout in 2022 midterms versus 52% for all ages — and is disproportionately decisive in competitive Senate and House races. Republican members with large senior populations in their districts face genuine political risk from any measure that would visibly raise drug prices.
The IRA negotiation program is structurally clever politics: the negotiated prices are set to take effect in stages aligned with election cycles, meaning senior voters will begin seeing tangible pharmacy cost reductions in 2026 and 2027. Repealing or undermining the program at this point would require explaining to seniors why their newly reduced drug costs are going back up. This has made even ardent IRA opponents in the Republican caucus reluctant to attack the negotiation program directly.
Trump's Contradictory Signals
Trump's public positioning on drug pricing is characteristically contradictory. He frequently claims credit for first-term executive orders on drug pricing (most of which were never implemented or were reversed in court). He has expressed support for the concept of Medicare negotiation as consistent with his populist brand. Simultaneously, pharmaceutical industry donors and lobbyists are major Republican Party supporters and have significant access to the administration.
The reconciliation bill navigates this contradiction by preserving the existing 10-drug negotiation program and the $35 insulin cap — protecting Republicans from the senior voter backlash — while blocking the program's expansion to additional drugs and future years. This satisfies pharmaceutical industry priorities (limiting future revenue losses) while insulating vulnerable Republicans from the charge that they raised drug prices. Democrats have attacked this as protecting industry profits at seniors' expense by preventing further expansion.
KFF (March 2026): Drug price negotiation is the most broadly popular healthcare policy in polling — 83% of Americans support it, including 77% of Republicans and 72% of self-identified conservatives. The $2,000 annual out-of-pocket cap for Medicare beneficiaries polls at 79% approval. No other healthcare policy in recent history has achieved this level of bipartisan public support.
Pharmaceutical companies subject to negotiation sued the federal government, arguing the negotiation process is unconstitutional coercion. Courts have uniformly rejected these claims. Industry has shifted strategy to lobbying for limiting future negotiation expansion and securing favorable tax treatment for R&D in the reconciliation bill. Total pharma lobbying spending hit a record $380M in 2025.
The IRA's $2,000 annual out-of-pocket cap for Medicare Part D, effective 2025, has direct financial impact on approximately 1.5 million beneficiaries who previously exceeded that threshold — many spending $5,000-$10,000+ annually on medications for cancer, MS, and other serious conditions. The average savings for those who hit the cap is $3,300/year. This is the most tangible Medicare improvement since the program's creation.
